Regeneus receives R&D tax incentive refund of $3.4m

Tuesday, 13 October 2015

Regeneus Ltd (ASX: RGS), a clinical-stage regenerative medicine company, today reported that it has received $3.4m from the Australian Government’s Research and Development Tax Incentive Program for activities conducted during the 2015 financial year.

The successful program is designed to encourage local R&D activities and support industry innovation.

Regeneus will use the funds to progress its regenerative medicine product pipeline and anticipates that it will be eligible to receive reimbursement for qualifying expenditure in its R&D programs during the financial year 2016.